Jump to content

Recommended Posts

Posted

Screenshot_0.jpg.1f33a39719dbea84bd693730ee1556d1.jpg

 

A large staggered cohort study from primary care patients in the UK, Spain, and Estonia finds that COVID-19 vaccination consistently reduced the risk of long-COVID symptoms. The study is published in The Lancet Respiratory Medicine.

...

In total, more than 10 million vaccinated people and 10 million unvaccinated people from each of the three countries and four databases were compared, and effectiveness of vaccination with either ChAdOx1 (AstraZeneca) and BNT162b2 (Pfizer-BioNTech) was assessed.

...

Across all four staggered cohorts in all three countries, vaccination was associated with a lowered risk of developing long COVID. And a slightly stronger preventative effect was seen for the first dose of BNT162b2 than for ChAdOx1, the authors said. Vaccine efficacy (VE) against long COVID ranged from 29% to 52%.

 

(more)

 

https://www.cidrap.umn.edu/covid-19/more-evidence-vaccination-reduces-risk-long-covid

 

 

"In conclusion, our study shows the clinical effectiveness of COVID-19 vaccines to prevent long COVID, highlighting yet another benefit of vaccination, particularly for adults. These findings were consistent across three European countries and different populations, and were robust to multiple definitions of long COVID and sensitivity analyses."

 

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00414-9/fulltext#seccestitle140

 

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.



×
×
  • Create New...